AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 22 min read$MAIA

Gryaznov Sergei purchased $3K of MAIA

Gryaznov Sergei (Chief Scientific Officer) purchased 2,000 shares of MAIA Biotechnology, Inc. (MAIA) at $1.34 on 2026-06-01.

Original reporting
SEC EDGAR · Gryaznov Sergei
Published Jun 2, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MAIA
Bullish
low confidence
Mentioned
$MAIA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MAIABullishLow
01

Why it matters

The disclosure adds sentiment context but does not provide new clinical, regulatory, or financial information.

02

Market read

Traders may view the purchase as a small positive signal, but the lack of fundamental updates limits trading edge.

03

What to watch

Check for follow-on Form 4s (size/frequency) and whether the purchase price diverges from recent trading levels; one small buy is not a trend by itself.

Relevance 4/10Novelty 3/10Timing: Filed pre-market today (2026-06-02) after trade date 2026-06-01.

Background

The filing is an SEC Form 4 insider transaction: Gryaznov Sergei (Chief Scientific Officer) purchased MAIA shares directly.

Company-level read

Ticker impact

$MAIABullishLow confidence
Context

SEC Form 4 shows MAIA’s Chief Scientific Officer bought 2,000 shares open-market at $1.3450 on 2026-06-01.

Expected impact

Likely limited near-term impact; any reaction should fade unless followed by larger buys or fundamental catalysts.

Evidence & confidence

This is an ownership-change filing (Form 4) with a modest dollar amount and no accompanying operational/financial news.

Market effects

Sector

Minimal; single-company insider transaction typically does not reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider purchases can be routine or tax/compensation-related; without a 10b5-1 plan, it still may not signal a new fundamental catalyst.

Key entities

  • issuer
    MAIA Biotechnology, Inc.

    Subject of the insider transaction disclosure via SEC Form 4.

  • insider
    Gryaznov Sergei

    Chief Scientific Officer who purchased 2,000 shares open-market.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MAIA insider trading history →

Related articles

OCT 7
$MAIAMedAI 8/10

MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%

MAIA Biotechnology (MAIA) announced completing enrollment for Part C of its Phase 2 THIO-101 trial and 65% completion for its Phase 3 THIO-104 trial, both evaluating ateganosine in NSCLC. The company reported a 90.5% interim disease control rate for the combination therapy. MAIA aims to enroll 100 patients in THIO-104 by 2026, with an interim analysis planned for 2027. The FDA granted Fast Track designation to ateganosine in July 2025. MAIA shares are up 0.85% at $1.20.

rttnews.com2 min
OCT 7
$MAIAMedAI 9/10

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

MAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.

globenewswire.com2 min